ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Ionis to acquire former subsidiary Akcea

by Ryan Cross
September 3, 2020 | APPEARED IN VOLUME 98, ISSUE 34

 

The antisense oligonucleotide company Ionis Pharmaceuticals will buy the 24% of Akcea Therapeutics stock that it does not already own for about $500 million. Ionis founded Akcea as a subsidiary to develop and commercialize experimental drugs Ionis designed. Akcea’s years of independence were marked by the US Food and Drug Administration’s rejection of its lead drug candidate, Waylivra, and competition for its second drug, Tegsedi. The firm has four drug candidates in Phase II and III trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment